9/20/2017. Effectively Managing Nausea and Vomiting. Disclosure. Objectives
|
|
- Earl Nichols
- 6 years ago
- Views:
Transcription
1 Effectively Managing Nausea and Myra Belgeri, Pharm.D, BCGP, BCPS, FASCP Clinical Pharmacist, Optum Hospice Pharmacy Services October Disclosure I have no relevant financial relationships with manufacturers of any commercial products and/or providers of commercial services discussed in this presentation. This discussion will include the use of medications for off-label indications. All medication treatments and doses discussed are only applicable to adult patients. 2 Objectives Review the pathophysiology and assessment of nausea and vomiting Develop a plan for the treatment of nausea and vomiting in hospice and palliative care 3 1
2 Patient Case Meet Mr. A Mr. A is a 70 year old with recently diagnosed cholangiocarcinoma that has metastasized to the liver and peritoneum. He is newly admitted to hospice and has been complaining of constant nausea for the past week. Hospice nurse finds a distressed patient who is slightly jaundiced. 4 Pathophysiology & Assessment Definitions Nausea Unpleasant subjective feeling that one will imminently vomit (emesis) Expulsion of gastric contents through the mouth May often have nausea without vomiting, or (less frequently) vice versa Most report nausea is more common and more disabling Other definitions Regurgitation: return of small amounts of gas or food from the stomach Retching: rhythmic movement of diaphragm to facilitate regurgitation into esophagus Dyspepsia: symptoms of the upper GI tract associated with early satiation, epigastric pain or burning, and nausea 6 2
3 Prevalence Advanced cancer patients up to 70% Palliative patients with non-malignant conditions up to 50% Opioid use up to 40% Reported more often by women than men Causes substantial psychological distress Creates fears of starvation, dehydration, or disease progression 7 Pathophysiology Gastric stasis Constipation, autonomic dysfunction Chemical disturbances Opioids, chemotherapy, any medication or chemical exposure Metabolic disturbances Hyperglycemia, hypercalcemia, hyponatremia, uremia Intestinal obstruction Abdominal malignancy, ileus Raised intracranial pressure CNS malignancy, trauma Vertigo Meniere s disease, labyrinthitis, head/neck malignancy Anxiety 8 Pathogenesis of Nausea/ The Emetogenic Pathway Chemoreceptor Trigger Zone Cerebral Cortex Vestibular System Center GI Tract 9 3
4 Vestibular System Vestibulocochlear nerve Carries input from inner ear to brainstem Labyrinthine inputs can trigger the vomiting center Triggers Movement in the inner ear Opioids Tumors at base of skull Presentation Intermittent symptoms Nausea/vomiting with position changes When raising the head of the bed, getting out of bed Nausea/vomiting with movement Walking, wheelchair movement, riding in a car Vestibular System Center 10 Chemoreceptor Trigger Zone (CTZ) Located outside the BBB in the CNS Exposed to toxins in the blood & cerebrospinal fluid Triggers Drugs (opioids, chemotherapy, SSRIs, antibiotics) Metabolic products (uremia, hypercalcemia) Comorbidities (organ failure, infection) Presentation Predominantly nausea, constant and often severe Aggravated by sight/smell of food does not significantly relieve nausea Physical exam often unremarkable Chemoreceptor Trigger Zone Center 11 Cerebral Cortex Receives input from the 5 senses Triggers Anxiety, recalling past events Irritation or increased intracranial pressure (ICP) Presentation Anxiety Waves of nausea, with or without vomiting Nausea may be relieved by distraction Increased ICP Diurnal headache, nausea (possibly diurnal) Neurological signs might be present Cerebral Cortex Center 12 4
5 Gastrointestinal (GI) Tract Input received from peripheral pathways Mechanoreceptors and chemoreceptors GI tract, viscera, serosa Input directed to both the CTZ and vomiting center Triggers Impaction, obstruction (stool, metastases) Autonomic dysfunction (e.g., Parkinson s) Medications (opioids, NSAIDs) GI bleeding, ulceration GI malignancy, liver disease, bile duct obstruction Local radiation GI Tract Center 13 Gastrointestinal (GI) Tract Presentation Gastric stasis Epigastric pain, fullness, nausea, early satiety, reflux large volumes; projectile vomiting relieves the nausea GI irritation Dark, tarry stools, coffee ground emesis Diarrhea, nausea, occasional vomiting, altered bowel habits GI Tract Center 14 Neurotransmitters in the Emetogenic Pathway Dopamine (D 2 ) Triggers nausea in the CTZ; receptors stimulated by products in the bloodstream and cerebrospinal fluid Agonism in the GI tract slows gut motility ( dopaminergic brake ) Serotonin (5HT 3, 5HT 4 ) Released in GI tract in response to toxins; signals the CTZ and vomiting center 5HT 4 impacts upper GI motility Histamine (H 1, H 2 ) Triggered by movement in the inner ear Contributes to cerebral cortex stimulations triggered by emotions or irritation Released in GI tract in response to toxins; signals the vomiting center H 2 involved in gastric acid secretion 15 5
6 Neurotransmitters in the Emetogenic Pathway Acetylcholine (ACh) and muscarinic receptors Released in GI tract in response to toxins; signals the vomiting center Contribute to cerebral cortex stimulations triggered by emotions or irritation Triggered by movement in the inner ear Neurokinin (NK 1 ) Triggers nausea in the CTZ and activates vomiting center Gamma-amino butyric acid (GABA) Agonism in the CNS can subside excitatory neurons contributing to anxious state 16 Neurotransmitters in the Emetogenic Pathway Chemoreceptor Trigger Zone D 2, 5HT 3, NK 1 Cerebral Cortex GABA, H 1 Vestibular System H 1, ACh Center H 1, ACh, 5HT, NK 1, mu GI Tract 5HT 4, 5HT 3, D 2, H 2, ACh 17 Assessment Is the nausea and/or vomiting constant or intermittent? Timing Does vomiting accompany the nausea? / Does nausea accompany the vomiting? Does vomiting relieve the nausea? Triggers Does the sight or smell of food trigger nausea? Do you become nauseated or vomit shortly after eating or drinking? Does movement trigger nausea or vomiting? Associated Symptoms Have there been any changes in bowel habits? Are you having bowel movements? Do you have any pain, anxiety, reflux, headache, confusion, or vision changes? 18 6
7 Assessment Medications Have you tried any treatments for your symptoms? Do they work? Have you been able to take any of your medications? Description Describe the quality of your emesis (amount, color, presence of undigested food, etc.) Describe the quality of your stool (amount, texture, color, etc.) 19 Patient Case Assessment Mr. A is a 70 year old with recently diagnosed cholangiocarcinoma that has metastasized to the liver and peritoneum. He is newly admitted to hospice and has been complaining of constant nausea for the past week. Hospice nurse finds a distressed patient who is slightly jaundiced. Constant background nausea with emesis about 30 minutes after eating Emesis relieves the nausea for a short period of time The smell of food makes the nausea worse; oral intake is poor Nausea not worsened by movement; patient still ambulates short distances Abdominal pain present constantly; started using morphine 5 mg doses with minimal relief Bowel movements are irregular; last BM was 2 days ago What might be the cause (pathogenesis) of Mr. A s nausea/vomiting? 20 Treatment Options 7
8 Treatment Approach Empiric treatment Use same medication for initial treatment regardless of presentation Less-preferred method among most hospice and palliative care practitioners Mechanism-based treatment Treatment selection guided by presentation of symptoms and knowledge of the emetogenic pathway Method used by most hospice and palliative care practitioners 22 Treatment Approach Dopamine antagonists 5HT 3 antagonists NK 1 antagonist Antihistamines Anticholinergics Anxiolytics Corticosteroids Prokinetics Miscellaneous 23 Dopamine Antagonists Haloperidol (Haldol ) Strong D 2 antagonism in the CTZ and GI tract Starting dose: 0.5 mg PO/SL/PR/IV/SC every 4 hours PRN Tablets and oral solution absorbed well SL and PR; versatile, low cost Low risk for side effects such as extrapyramidal symptoms at low starting dose Caution QT prolongation Prochlorperazine (Compazine ) Strong D 2 antagonism, weak H 1 antagonism Starting dose: 10 mg PO every 6 hours PRN or 25 mg supp PR every 12 hours PRN Must use tablets PO and suppositories PR; suppositories are high cost Antihistamine effect causes more sedation than haloperidol 24 8
9 Dopamine Antagonists Chlorpromazine (Thorazine ) Strong D 2 antagonism, weak H 1 antagonism, weak anticholinergic activity, strong alpha-adrenergic blocker Starting dose: 25 mg PO/IV every 6 hours PRN High risk for orthostatic hypotension and sedation Promethazine (Phenergan ) Strong H1 antagonism, weak D2 antagonism, moderate anticholinergic activity Starting dose: 12.5 mg PO/PR/IV/IM every 6 hours PRN Very sedating; might be most useful for stopping emesis Suppositories are high cost 25 5HT 3 and NK 1 Antagonists Ondansetron (Zofran ) Selective 5HT 3 antagonist Prevention of chemotherapy-induced, radiation-induced, or post-operative nausea/vomiting Appropriate to continue use for 1-2 weeks beyond the related procedure Starting dose: 8-24 mg PO/IV prior to chemo or surgery (dose and route dependent on indication) May be a last-line therapy in hospice for CTZ nausea/vomiting Acquisition cost is high and cost at the pharmacy varies Caution constipation and QT prolongation Aprepitant (Emend ) Selective NK1 antagonist Used in combo with a 5HT 3 antagonist and dexamethasone for emetogenic chemotherapy Appropriate to continue per dosing schedule for prevention of nausea, usually 1-3 days 26 Antihistamines Meclizine (Antivert, Dramamine Less Drowsy) H 1 antagonism with some central anticholinergic activity Starting dose: 25 mg PO every 6 hours PRN Sedating, but possibly the least sedating of the antihistamines with antiemetic effects Drug of choice for vertigo; available OTC Anticholinergic side effects (dry mouth, confusion, constipation, urinary retention, blurred vision) Other antihistamines for vestibular nausea Hydroxyzine (Vistaril, Atarax ) Promethazine (strong H 1 effect) 27 9
10 Anticholinergics Scopolamine (Transderm-Scop ) Strong antimuscarinic (anticholinergic) and some H 1 antagonism Dose: Apply 1 transdermal patch (1.5 mg) to hairless area behind ear every 72 hours Good for prophylaxis and treatment of motion sickness; blocks the vomiting center Do not cut patches; best if placed 4-12 hours prior to anticipated need for motion sickness Side effects: sedation, constipation, urinary retention, dry mouth, confusion, tachycardia Other anticholinergics Glycopyrrolate (Robinul ) Does not cross BBB, less sedation; most useful in full bowel obstruction Hyoscyamine (Levsin ) Short half life and need for repeated dosing complicates chronic use Might already be in the patient s home for terminal secretions 28 Anxiolytics Benzodiazepines e.g., lorazepam (Ativan ), alprazolam (Xanax ), diazepam (Valium ) GABA-A receptor agonists; GABA causes inhibition of CNS excitement Best for anticipatory nausea/vomiting or anxiety related causes Any benzodiazepine would work for this cause; choice based on patient-specific factors Hydroxyzine Antihistamine with weak anxiolytic properties Also anticholinergic action; caution side effects (dry mouth, constipation, urinary retention, confusion, sedation) Starting dose: 25 mg PO q6h PRN Will also have an effect on the vomiting center 29 Corticosteroids Dexamethasone (Decadron ) Readily crosses BBB to provide relief of raised intracranial pressure Starting dose: 4 mg PO/PR/SC/IV BID in the morning and early afternoon Giving a dose close to bedtime can cause insomnia In brain malignancy, the dose may need to be titrated every few weeks Useful as an adjunct for other causes, such as chemotherapy induced nausea/vomiting Take with food to avoid GI irritation Other corticosteroids Methylprednisolone (Medrol ) may also cross the BBB Dexamethasone has the most evidence to support use 30 10
11 Prokinetics Metoclopramide (Reglan ) Strong D 2 antagonism, moderate 5HT 4 agonism, some 5HT 3 antagonism in high doses Starting dose: 5-10 mg PO/PR/IV/IM/SC 30 minutes before meals and at bedtime Prokinetic effect in the upper GI tract through 5HT 4 agonism and release of dopaminergic brake Also useful in CTZ nausea and partial bowel obstruction Caution EPS/TD and QT prolongation; use smallest dose for shortest period of time Other prokinetic Erythromycin 250 mg PO TID before meals Gastric motilin agonist May have a place in therapy for those unable to take metoclopramide Macrolide antibiotic; caution risk of QT prolongation Limit use to 4 weeks or less due to drop in efficacy and risk of tachyphylaxis 31 Miscellaneous Therapies Olanzapine (Zyprexa ) Affinity for many receptors in the emetic pathway: D 2, various 5HT, H 1, Ach Studied in chemotherapy-induced nausea/vomiting Case reports available for palliative care population Starting dose for palliative care: 5 mg PO at bedtime Less risk for EPS than with strong dopamine antagonists Side effects: sedation, dry mouth, constipation, weight gain, hyperglycemia May exert action on several portions of the emetogenic pathway Good option for nausea/vomiting refractory to other therapies Acid suppression agents Proton pump inhibitors (omeprazole, lansoprazole) H 2 antagonists (ranitidine, famotidine) 32 Miscellaneous Therapies Cannabinoids CB 1 cannabinoid receptors are found throughout the CNS, brainstem, GI tract and rest of the body CB 1 receptor agonists such as Δ 9 -THC from the cannabis plant have an effect on nausea and vomiting Two FDA-approved cannabinoids: dronabinol (Marinol ) and nabilone (Cesamet ) Not more effective than traditional antiemetics; high cost Only approved for chemotherapy-induced nausea/vomiting Current knowledge of role in mechanisms of N/V outside chemotherapy is limited Schedule III controlled substance; potential for dependence Lowers seizure threshold; may cause hypotension and syncope 33 11
12 Opioid-Induced Nausea/ (OINV) Multiple emetogenic pathways involved Chemoreceptor trigger zone Gastroparesis and constipation Sensitization of the vestibular nerve Generally occurs with opioid initiation or dose escalation Tolerance develops after 3-5 days of continued use Treatment OINV is largely mediated through D 2 receptors Schedule a D 2 antagonist around the clock for several days, then taper and d/c Haloperidol is a good choice with demonstrated efficacy and minimal sedation Metoclopramide has also demonstrated efficacy Other dopamine antagonists may be limited in use due to side effects and worsening sedation Could also attempt to lower opioid dose by 10-20%, but may compromise pain control 34 Take Note! People develop tolerance to the nauseating effects of opioids typically within 3-5 days of use. If the opioid dose cannot be reduced without compromising pain control, schedule haloperidol 0.5 mg PO every 8 hours for 7 days then taper and discontinue. 35 Treatment Approach Mechanism-based Vestibular H 1, ACh Chemoreceptor Trigger Zone D 2, 5HT 3, NK 1 Cerebral Cortex GABA, H 1 GI Tract 5HT 4, 5HT 3, D 2, H 2, ACh Antihistamines Anticholinergics Dopamine agonists Anxiolytics Corticosteroids Prokinetics Selective 5HT 3 antagonists Selective NK 1 antagonist 36 12
13 Patient Case Treatment Mr. A is a 70 year old with recently diagnosed cholangiocarcinoma that has metastasized to the liver and peritoneum. He has been determined to have nausea related to gastric stasis and CTZ based on the following: Emesis 30 minutes after eating; temporarily relieves the nausea New opioid use morphine started for abdominal pain Bowel movements are irregular with last BM 2 days ago Nausea is constant and worsened by the smell of food What would be the best treatment for Mr. Armstrong s symptoms? 37 Treatment Tips When first selection is not working, do we add or remove? Multifactorial symptom, may be best to add Choose a medication with a different mechanism of action Also first consider titration of the initial agent if partial response Beware polypharmacy Prokinetics + anticholinergics = counter-intuitive e.g., avoid promethazine with metoclopramide Multiple dopamine antagonists = high risk for EPS e.g., haloperidol with metoclopramide Multiple QT prolonging medications = arrhythmia risk e.g., haloperidol, ondansetron 38 Treatment Tips Major antiemetic drug-disease interactions Seizures Most antiemetics can lower seizure threshold; use with caution Parkinson s disease Caution EPS and worsening Parkinson s symptoms with dopamine antagonists Best options: promethazine, ondansetron Dementia with Lewy bodies High risk of neuroleptic malignant syndrome with potent dopamine antagonists Reported mostly with typical (first-generation) antipsychotics such as haloperidol and chlorpromazine Best options: promethazine, ondansetron 39 13
14 Treatment Tips When empiric treatment approach is necessary Sudden onset of vomiting at 3am and patient needs immediate relief! Might be the only place in therapy for compounded multi-ingredient products ABHR suppositories hits D 2, H 1, ACh, GABA, 5HT 4 Provides symptom relief until a thorough assessment can be performed Topical products unlikely to provide relief Hospice medication of choice for empiric treatment: haloperidol Covers most common causes of nausea/vomiting in terminal patients Versatile medication Highly lipophilic, absorbed well via rectal and sublingual routes Not sedating in low doses; low cost 40 Patient Case Refractory Symptoms Mr. A is a 70 year old with recently diagnosed cholangiocarcinoma that has metastasized to the liver and peritoneum. He started using metoclopramide 10 mg by mouth before meals and at bedtime last week for nausea and vomiting related to gastric stasis. He also started senna/docusate 8.6/50 mg 2 tablets at bedtime for constipation due to morphine use. He is now happy to report daily bowel movements and no more episodes of vomiting. However, he still reports constant, mild to moderate nausea that is worsened by the smell of food. He is troubled by being unable to enjoy some of his favorite meals. He has an expired bottle of promethazine tablets in the home and is asking if he can use those for the nausea. What is the best plan for treatment? 41 Key Points Have a working knowledge of the emetogenic pathway Understand that nausea and vomiting are multifactorial conditions Know how symptom presentation is linked to underlying cause/pathway Patient assessment is key! Have a mental or actual checklist of assessment items Use knowledge of the emetogenic pathway to select mechanism-based treatments Assessing the patient and moving to mechanism-based treatments can quickly manage the symptom and lessen adverse drug effects 42 14
15 Questions? Myra Belgeri, Pharm.D, BCGP, BCPS, FASCP 43 References 1. Glare PA, Dunwoodie D, Clark K, et al. Treatment of nausea and vomiting in terminally ill cancer patients. Drugs 2008; 68(18): Wood GJ, Shega JW, Lynch B, et al. Management of intractable nausea and vomiting in patients at the end of life. JAMA 2007; 298(10): Collis E, Mather H. Nausea and vomiting in palliative care. BMJ 2015; 351: Neoh K, Adkinson L, Montgomery V, et al. Management of nausea and vomiting in palliative care. Br J Hosp Med 2014; 75(7): Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. Ther Adv Gastroenterol 2016; 9(1): Tornblom H, Abrahamsson H. Chronic nausea and vomiting: insights into underlying mechanisms. Neurogastroenterol Motil 2016; 28: Prommer E. Role of haloperidol in palliative medicine: an update. Am J Hosp Palliat Med 2012; 29(4): Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013; 108: References 9. Chu CC, Hsing CH, Shieh JP, et al. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. Eur J Pharmacol 2014; 722: Kim JS, Sung HY. Gastrointestinal autonomic dysfunction in patients with Parkinson s disease. J Mov Disord 2015; 8(2): MacKintosh D. Olanzapine in the management of difficult to control nausea and vomiting in a palliative care population: a case series. J Palliat Med 2016; 19(1): Ang SK, Shoemaker LK, Davis MP. Nausea and vomiting in advanced cancer. Am J Hosp Palliat Med 2010; 27(3): Gordon P, LeGrand SB, Walsh D. Nausea and vomiting in advanced cancer. Eur J Pharmacol 2014; 722: Sharkey KA, Darmani NA, Parker LA. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol 2014; 722: Smith HS, Laufer A. Opioid induced nausea and vomiting. Eur J Pharmacol 2014; 722:
Symptom Management. Thomas McKain, MD, ABFM, ABHPM Medical Director
Symptom Management Nausea & Vomiting Thomas McKain, MD, ABFM, ABHPM Medical Director Mr. Jones has nausea and vomiting. May I initiate Compazine from the Comfort Pak? Objectives 1. Delineate the Differential
More informationNausea and Vomiting in Palliative Care
Nausea and Vomiting in Palliative Care Definitions Nausea - an unpleasant feeling of the need to vomit Vomiting - the expulsion of gastric contents through the mouth, caused by forceful and sustained contraction
More informationGI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi
GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics Dr. Alia Shatanawi 11-04-2018 Drugs used in Irritable Bowel Syndrome Idiopathic, chronic, relapsing disorder characterized by abdominal discomfort
More informationNausea. Assessment & Management. R J Crossno, MD, CMD, FAAFP, FAAHPM. Disclosures
Nausea Assessment & Management R J Crossno, MD, CMD, FAAFP, FAAHPM Disclosures Dr. Crossno discloses his employment as Area Medical Director for VistaCare VistaCare has provided commercial support for
More informationApproach to Nausea & Vomi2ng
Approach to Nausea & Vomi2ng Med 3 Seminar 2017 Dr. Robin Grant Division of Pallia2ve Medicine robin.grant@nshealth.ca Why nausea and vomi2ng? Pain 80-90+ % Fa2gue / asthenia 75-90% Cons2pa2on 70% Dyspnea
More informationNausea & Vomiting. Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA
Nausea & Vomiting Dr Eve Lyn TAN Liverpool Hospital NSW, AUSTRALIA Prevalence prevalence varies *, systemic review 2007 : overall prevalence : nausea 30%, vomiting 20% in last 1-2 weeks of life : nausea
More informationDECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it***
Decontamination and Antiemetics Med 5724 Page 1 of 8 DECONTAMINATION AGENTS and ANTIEMETICS *** This material won t be covered in lecture, but you are responsible for it*** REFERENCES: Katzung (9th ed.)
More informationFirst a caution. Processes we might NOT try to treat with medications. Processes we might try to treat. Main drug categories.
Pharmacological Interventions for dizziness Timothy C. Hain, MD Northwestern University Medical School Chicago, Illinois, USA First a caution Torok N. Old and new in Meniere's disease. Laryngoscope 87:1870-1877,
More informationDelirium and Nausea. Delirium - definition. Delirium Incidence. Predisposing Risk Factors for Delirium. Impact. Delirium Types 10/14/2016
Delirium - definition Delirium and Nausea Etiologically non-specific global cerebral dysfunction associated with changes in LOC, attention, thinking, perception, memory, psychomotor behavior, emotion and
More informationFive Centers of Nausea. Linda Tavel, MD Program Medical Director VistaCare Hospice
Five Centers of Nausea Linda Tavel, MD Program Medical Director VistaCare Hospice Objectives Prevalence of nausea and vomiting Anatomic and physiologic paths to nausea Evaluation of nausea Treatment of
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationFirst a caution. Processes we might NOT try to treat with medications. Processes we might try to treat. Main drug categories.
Pharmacological Interventions for dizziness Timothy C. Hain, MD Northwestern University Medical School Chicago, Illinois, USA First a caution Torok N. Old and new in Meniere's disease. Laryngoscope 87:1870-1877,
More informationA SLP s Guide to Medication Therapy and Management. Sarah Luby, PharmD, BCPS KSHA 2017
A SLP s Guide to Medication Therapy and Management Sarah Luby, PharmD, BCPS KSHA 2017 Objectives Identify the appropriate route of administration for medications and proper formulations for use Understand
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationNausea and Vomiting. Principles and Practice in End of Life Care November 2018
Nausea and Vomiting Principles and Practice in End of Life Care November 2018 Overview Aims and Objectives Why is managing nausea and vomiting important? Definitions Causes Interventions pharmacological
More informationSymptom Management Challenges at End-of-Life
Symptom Management Challenges at End-of-Life Amanda Lovell, PharmD, BCGP Clinical Pharmacist- Inpatient Units Optum Hospice Pharmacy Services February 15, 2018 Hospice Pharmacy Services Objectives Identify
More informationManagement of Delirium in Hospice Patients
Presentation Objectives Management of Delirium in Hospice Patients Lynn Williams, BSPharm Clinical Pharmacist Hospice Pharmacy Solutions Identify the clinical features of delirium Understand the underlying
More informationVomiting Approach to diagnosis
Vomiting Approach to diagnosis By Dr. Sahar El-Gharabawy Associate professor of internal medicine Hepato-gastroenterology Unit )SMH ) Mansoura University Definitions: Nausea: Feeling "sick to the stomach",
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationDisclosures 9/17/2018. Best Practices in the Treatment of Nausea and Vomiting
Best Practices in the Treatment of Nausea and Vomiting Jennifer Gabbard, MD Wake Forest School of Medicine jgabbard@wakehealth.edu 42 nd Annual Hospice & Palliative Care Conference September 2018 Charlotte,
More informationUsing Evidence Based Medicine to Ethically Provide End of Life Symptom Control
Using Evidence Based Medicine to Ethically Provide End of Life Symptom Control Erin Zimny, MD Emergency Medicine Hospice and Palliative Medicine Henry Ford Hospital Disclosures I do NOT have any financial
More informationIf we are going to treat this, of course it's like most things, we want to treat the underlying cause as well as the effect.
Systemic Management of Nausea: Antiemetics Bruce Flint O.D. Antiemetics: This is for controlling nausea and vomiting. These are multiple conditions that's causing this. It's kind of common. I'm sure all
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium Goals and Objectives: Describe
More informationManagement of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients
Management of Chemotherapy Induced Nausea/Vomiting(CINV) in Adult Cancer Patients By Zahra Shaghaghi, Pharm-D, BCOP, PhC Prepared for 2018 NMSHP Balloon Fiesta Symposium 1 Goals and Objectives: Describe
More informationLearning Objectives. Delirium. Delirium. Delirium. Terminal Restlessness 3/28/2016
Terminal Restlessness Dr. Christopher Churchill St. Cloud VA Health Care System EC&R Service Line Director & Medical Director Hospice & Palliative Care March 31, 2016 Learning Objectives Different Terminology
More informationPart 2: Pain and Symptom Management Nausea and Vomiting
Part 2: Pain and Symptom Management Nausea and Vomiting Effective Date: February 22, 2017 Key Recommendations Select anti-nausea medication based on the etiology of the nausea and vomiting. Assessment
More informationNeuro Basics SLO Practice (online) Page 1 of 5
Neuro Basics SLO Practice (online) Page 1 of 5 1) Biogenic amines include ACh, NE, EPI and? a) Melatonin b) Dopamine c) Serotonin d) Histamine e) All of the neurotransmitters listed are biogenic amines.
More information3/27/2013. Objectives. Psychopharmacology at the End of Life Nicole Thurston, MD
Psychopharmacology at the End of Life Nicole Thurston, MD Psychiatrist Mountain States Tumor Institute Objectives Describe 2 common psychiatric symptoms that can present at or near end of life. Review
More informationControlling nausea and vomiting: anti-emetic therapy advice
Controlling nausea and vomiting: anti-emetic therapy advice Chemotherapy A guide for patients and carers Contents Treatments that may cause nausea and vomiting... 2 Physical reasons that may cause nausea
More informationGeneric (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Nausea LAST REVIEW 9/11/2018 THERAPEUTIC CLASS Gastrointestinal Disorders REVIEW HISTORY 12/16, 11/15, 11/07 LOB AFFECTED
More informationChapter 29 - Nausea and Vomiting
Chapter 29 - Nausea and Vomiting Episode Overview: 1) Describe the mechanism of development of a Hypochloremic Metabolic Alkalosis in vomiting 2) List commonly used anti-emetics including their dose and
More informationA RANDOMISED, OPEN LABEL STUDY OF GUIDELINE DRIVEN TARGETED ANTIEMETIC THERAPY VERSUS SINGLE AGENT ANTIEMETIC THERAPY
A RANDOMISED, OPEN LABEL STUDY OF GUIDELINE DRIVEN TARGETED ANTIEMETIC THERAPY VERSUS SINGLE AGENT ANTIEMETIC THERAPY Patsy Yates, Janet Hardy, Peter Martin, Jennifer Philip, Peter Hudson, David Currow,
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSAEMS. Ondansetron HCL Self-Learning Module
SAEMS Ondansetron HCL Self-Learning Module Dawn Daniels Tucson Medical Center November, 2008 1 DATE: November 2008 PURPOSE TRAINING MODULE FOR ONDANSETRON This Training Module has been developed to serve
More informationConflicts of Interest. Review of Antiemetic Guidelines. Learning Objectives. What is Emesis Anyways? Pharmacy Technician Learning Objectives
Conflicts of Interest No financial relationships to disclose Review of Antiemetic Guidelines Matthew Fox, PharmD, BCPS, BCOP Clinical Oncology Pharmacist Baptist MD Anderson Jacksonville, Florida October
More informationInpatient Palliative Medicine Update
Inpatient Palliative Medicine Update David Dupere MD, FRCPC Head, Division of Palliative Medicine Department of Medicine QEII Health Sciences Centre Halifax, Nova Scotia Disclosures Book chapter in Compendium
More informationPharmacology. Drugs that Affect the Gastrointestinal System
Pharmacology Drugs that Affect the Gastrointestinal System Topics Peptic Ulcer Disease Constipation Diarrhea Emesis Digestion Peptic Ulcer Disease Factors that Increase Acidity Factors that Protect Against
More informationCannabinoids and Mental Health
Cannabinoids and Mental Health https://upload.wikimedia.org/wikipedia/commons Karen M. Lounsbury, PhD Professor of Pharmacology 802-656-3231, Karen.lounsbury@uvm.edu Objectives Describe the underlying
More informationIBS Irritable Bowel syndrome Therapeutics II PHCL 430
Salman Bin AbdulAziz University College Of Pharmacy IBS Irritable Bowel syndrome Therapeutics II PHCL 430 Email:- ahmedadel.pharmd@gmail.com Ahmed A AlAmer PharmD R.S is 32-year-old woman experiences intermittent
More informationAgitation Excessive physical or mental restlessness. Increased activity that is generally not purposeful and associated with anxiety.
October 2012 4 Agitation Excessive physical or mental restlessness. Increased activity that is generally not purposeful and associated with anxiety. Depending on appropriateness, evaluate for reversible
More informationAntiemetics in chemotherapy
Antiemetics in chemotherapy Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission Date
More informationHMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in
HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time
More informationPRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist
PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines
More informationCYCLIC VOMITING SYNDROME. C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis
CYCLIC VOMITING SYNDROME C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis Case 26 year old male Symptoms began at age 19 yr 5-6 day episodes of recurrent, severe vomiting
More informationWorshipping at the Porcelain Altar: Nausea and Vomiting
Worshipping at the Porcelain Altar: Nausea and Vomiting EDUARDO GODOY, MD FAMILY MEDICINE, SOUTH BAY MEDICAL CENTER TORRANCE MOB Financial Disclosures: I have no financial ties other than those owed: to
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationLESSON ASSIGNMENT. Emetics, Antiemetics, and Antidiarrheals. After completing this lesson, you should be able to:
LESSON ASSIGNMENT LESSON 3 Emetics, Antiemetics, and Antidiarrheals. LESSON ASSIGNMENT Paragraphs 3-1 through 3-8. LESSON OBJECTIVES After completing this lesson, you should be able to: 3-1. Given one
More informationDOMPERIDONE BNF 4.6. Domperidone is a dopamine type 2-receptor antagonist. It is structurally related to the
DOMPERIDONE BNF 4.6 Class: Prokinetic anti-emetic. Indications: Nausea and vomiting, dysmotility dyspepsia, gastro-oesophageal reflux. Pharmacology Domperidone is a dopamine type 2-receptor antagonist.
More informationSecond term/
Second term/ 2015-2016 L. 1 Dr Mohammed AL-Zobaidy Learning objectives GIT pharmacology After completing this chapter the student will be able to: Recognise pathophysiological factors implicated in acid-peptic
More informationIntroduction & Expectations Learning Objectives Etiology & Pathophysiology of Nausea & Vomiting Pharmacology of Dimenhydrinate...
Primary Care Paramedic Dimenhydrinate (Gravol) Certification Learner Package www.lhsc.on.ca/bhp 1 Table of Contents Introduction & Expectations... 4 Learning Objectives... 4 Etiology & Pathophysiology
More informationVOMITING. Tan Lay Zye
VOMITING Tan Lay Zye Vomiting is a common symptom. It is a complex reflex behavioural response involving forceful expulsion of the stomach contents through oral cavity. Contents Emetic reflex Causes of
More informationCare in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationSomatostatin analogues. Other drugs
Octreotide Somatostatin analogues Lack the adverse effects of antimuscarinic agents Somatostatin decreases the release of gastrin, insulin, glucagon, gastric acid and pancreatic enzymes Also inhibits neurotransmission
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationUsing a Simple Diary for Management of Nausea and Vomiting During Chemotherapy
Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy Problem identification Nausea and vomiting (N&V) are frequent complications following chemotherapy, even when taking 5-HT3
More informationNon-opioid and adjuvant pain management
Non-opioid and adjuvant pain management ALLISON JORDAN, MD, HMDC MEDICAL DIRECTOR OF PALLIATIVE CARE SERVICES CHRISTIAN AND ALTON MEMORIAL HOSPITALS ASSOCIATE MEDICAL DIRECTOR, BJC HOSPICE ASSISTANT PROFESSOR
More informationZofran for motion sickness
Zofran for motion sickness The star of the motion sickness natural remedies line up has to be ginger! Although it doesn't work for everyone, lots of people find it very effective indeed. 4-3-2018 What
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationGrace Ma and Andrea Weiss FMF 2018
Grace Ma and Andrea Weiss FMF 2018 Presenter: Grace Ma Relationships with financial sponsors: none Presenter: Andrea Weiss Relationships with financial sponsors: none This program has not received any
More informationPage 1 of 6 PATIENT PRESENTATION PROPHYLAXIS. No risk factors from the categories
Page 1 of 6 PATIENT PRESENTATION PROPHYLAXIS risk factors from the categories listed below more than one drug prophylaxis (see Appendix A for antiemetic choices) Patient scheduled for surgery Assess patient
More information2018 Perioperative Management of PDNV
2018 Perioperative Management of PDNV Edward C. Adlesic, DMD Assistant Professor Oral and Maxillofacial Surgery Assistant Professor Dental Anesthesiology University of Pittsburgh School of Dental Medicine
More informationAUTACOIDS. Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan April, 2014
AUTACOIDS Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan April, 2014 AUTACOIDS Endogenous substances with complex physiologic and pathphysiologic functions; commonly understood
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationNausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea
Nausea and Vomiting: The Continuing Battle to Improve Outcomes Jan Tipton, MSN, RN, AOCN Oncology CNS Medical University of Ohio Toledo, Ohio jtipton@meduohio.edu Nausea and Vomiting Team Jan Tipton, MSN,
More informationPediatric Pharmacotherapy 101: Gastrointestinal Symptom Management
Pediatric Pharmacotherapy 101: Gastrointestinal Symptom Management Melissa Hunt, PharmD Pediatric Clinical Pharmacist Optum Hospice Pharmacy Services Cortney Rogers, PharmD, BCPPS Clinical Pharmacy Supervisor
More informationAdvanced Symptom Management
Advanced Symptom Management Janet Bull, MD, FAAHPM Four Seasons Symptom Management o Objectives Define symptom clusters and the role of cytokines Identify different clusters and treatment options Describe
More informationObjectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia
Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used
More informationAntidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych
Antidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych A. Heterocyclic antidepressants: (tricyclic and tetracyclic ), e.g.amitryptaline,imipramine. B. Monoamine oxidase inhibitors(m.a.o.i), e.g.phenelzine.
More informationLab:2 Drugs acting on Gastrointestinal tract
Lab:2 Drugs acting on Gastrointestinal tract Drugs that used to treat three common medical conditions involving the gastrointestinal tract: peptic ulcers and gastroesophageal reflux disease (GERD), chemotherapy-induced
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationManagement of Postoperative Nausea and Vomiting in Ambulatory Surgery The Big Little Problem
Management of Postoperative Nausea and Vomiting in Ambulatory Surgery The Big Little Problem Mary Keyes, MD KEYWORDS Postoperative nausea and vomiting PONV prophylaxis PONV in ambulatory surgery KEY POINTS
More informationNumber of studies. Endoscopic finding. Number of subjects. Pooled prevalence 95% CI
Clinical Approach to the Patient t with Dyspepsia William D. Chey, MD, FACG Professor of Medicine University of Michigan Prevalence of Endoscopic Findings in Individuals with Dyspepsia Systematic Review
More informationSymptom Management Pocket Guides: DELIRIUM
Symptom Management Pocket Guides: DELIRIUM August 2010 DELIRIUM Page Considerations. 1 Assessment 2 Diagnosis. 3 Non-Pharmacological treatment 3 Pharmacological treatment. 5 Mild Delirium... 6 Moderate
More informationHow does valium help with vertigo
Cari untuk: Cari Cari How does valium help with vertigo Learn about vertigo cures, treatment, causes, symptoms, exercises, diagnosis, home remedies, and more. Discover what you can do to treat vertigo
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationDelirium. Assessment and Management
Delirium Assessment and Management Goals and Objectives Participants will: 1. be able to recognize and diagnose the syndrome of delirium. 2. understand the causes of delirium. 3. become knowledgeable about
More informationEDUCATION PRACTICE. Management of Delayed Gastric Emptying. Clinical Scenario. The Problem. Management Strategies and Supporting Evidence
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:642 646 EDUCATION PRACTICE Management of Delayed Gastric Emptying FRANK K. FRIEDENBERG and HENRY P. PARKMAN Temple University Hospital, Philadelphia, Pennsylvania
More informationNursing Process Focus: Patients Receiving Chlorpromazine (Thorazine)
Nursing Process Focus: Patients Receiving Chlorpromazine (Thorazine) Potential Nursing Diagnoses Ineffective Therapeutic Regimen Management Risk for Activity Intolerance, related to side effect of drug
More informationGeri-PARDY! (2015 Beers Criteria) Pharmacology Edition
Geri-PARDY! Pharmacology Edition (2015 Beers Criteria) Aurelio Muyot, MD, AGSF, FACP Assistant Professor College of Osteopathic Medicine Touro University Nevada Objectives Review the 2015 Beers Criteria
More informationSymptom Management for Patients Near End of Life
Symptom Management for Patients Near the End of Life Ritchell R. Dignam, MD Medical Director Vitas Healthcare 856-778-0222 Objectives Review the etiology and pathophysiology of common non-pain symptoms
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationMedications used for symptom control in palliative care
Learning Objectives used for symptom control in palliative care Luis Viana, R. Ph., M.Ed., CGP 1. For common symptoms experienced by the person managed with palliative care: Recognize the symptom to be
More informationConstipation and bowel obstruction
Constipation and bowel obstruction Constipation Infrequent or difficult defecation with reduced number of bowel movements, which may or may not be abnormally hard with increased difficulty or discomfort
More informationCopy right protected Page 1
DRUGS USED IN ULCERS AND GIT DISORDERS A peptic ulcer, also known as PUD or peptic ulcer disease is an ulcer of an area of the gastrointestinal tract that is usually acidic and thus extremely painful.
More informationNausea and Vomiting During Pregnancy. Reassuring, with rare exception, that your pregnancy is healthy
1 Nausea and Vomiting During Pregnancy Keith Merritt, MD Overview Common problem affecting 50-90% of pregnancies between 5 and 18 weeks o Peaks, in most, around 9 weeks o Resolves, in most, by 16 to 18
More informationPalliative Medicine in Critical Care Not Just Hospice. Robin. Truth or Myth 6/11/2015. Francine Arneson, MD Palliative Medicine
Palliative Medicine in Critical Care Not Just Hospice Francine Arneson, MD Palliative Medicine Robin 45 year old female married, husband in Afghanistan. 4 children ages 17-24. Mother has been providing
More informationSymptom Control in Heart Failure. Dr Claire L Hookey
Symptom Control in Heart Failure Dr Claire L Hookey Heart Failure symptoms Class III/IV CHF, mean 67.1 years, mean EF 22.3% Most prevalent symptoms:- lack of energy (66%) dry mouth (62%) shortness of breath
More informationInsomnia: Updates in Medical Management. Michael Newnam M.D.
Insomnia: Updates in Medical Management Michael Newnam M.D. Sleep Neurobiology Delicate balance of excitatory and inhibitory neurotransmitters that control the switch between wakefulness and sleep Circadian
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationDYSPEPSIA Dyspepsia indigestion during or after eating Full Heat, burning or pain Note: one of every four people
What Is Dyspepsia? Dyspepsia, also known as indigestion, can have multiple symptoms. Feelings of indigestion happen during or after eating. If you have indigestion you might feel: Full during a meal. Painful
More informationAttach patient label here. Physician Orders ADULT: Palliative Care Plan
Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase T;N, Phase: Palliative Care Phase, When to Initiate: Palliative Care Phase Admission/Transfer/Discharge Patient Status Initial
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More informationFull details and resource documents available:
Clinical & Regulatory News by Pharmerica Urinary Tract Infection (UTI) Second Most Common Cause of Hospital Readmission within 30 days UTIs are prevalent and account for up to 22% of infections in LTC,
More informationAppropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this
More informationAnxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anxiolytic, Sedative and Hypnotic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Anxiolytics: reduce anxiety Sedatives: decrease activity, calming
More informationDelirium. Dr. Lesley Wiesenfeld. Deputy Psychiatrist in Chief, Mount Sinai Hospital. Dr. Carole Cohen
Delirium Dr. Lesley Wiesenfeld Deputy Psychiatrist in Chief, Mount Sinai Hospital Dr. Carole Cohen Department of Psychiatry, University of Toronto and Sunnybrook Health Sciences Centre Case Study Mrs B
More information